

1-1 By: Zerwas, et al. (Senate Sponsor - Kolkhorst) H.B. No. 2174
 1-2 (In the Senate - Received from the House April 26, 2019;
 1-3 April 29, 2019, read first time and referred to Committee on Health
 1-4 & Human Services; May 19, 2019, reported favorably by the following
 1-5 vote: Yeas 8, Nays 1; May 19, 2019, sent to printer.)

1-6 COMMITTEE VOTE

	Yea	Nay	Absent	PNV
1-7 Kolkhorst	X			
1-8 Perry	X			
1-9 Buckingham	X			
1-10 Campbell	X			
1-11 Flores	X			
1-12 Johnson	X			
1-13 Miles	X			
1-14 Powell	X			
1-15 Seliger		X		

1-17 A BILL TO BE ENTITLED
 1-18 AN ACT

1-19 relating to controlled substance prescriptions and reimbursement
 1-20 for treatment for certain substance use disorders; authorizing a
 1-21 fee.

1-22 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-23 SECTION 1. Section 552.118, Government Code, is amended to
 1-24 read as follows:

1-25 Sec. 552.118. EXCEPTION: CONFIDENTIALITY OF OFFICIAL
 1-26 PRESCRIPTION PROGRAM INFORMATION. Information is excepted from the
 1-27 requirements of Section 552.021 if it is:

1-28 (1) information on or derived from an official
 1-29 prescription form filed with the Texas State Board of Pharmacy
 1-30 under Section 481.0755, Health and Safety Code, or an electronic
 1-31 prescription record filed with the Texas State Board of Pharmacy
 1-32 under Section 481.075, Health and Safety Code; or

1-33 (2) other information collected under Section 481.075
 1-34 or 481.0755 of that code.

1-35 SECTION 2. Sections 481.002(10) and (47), Health and Safety
 1-36 Code, are amended to read as follows:

1-37 (10) "Designated agent" means an individual
 1-38 designated under Section 481.074(b-2) [481.073] to communicate a
 1-39 practitioner's instructions to a pharmacist in an emergency.

1-40 (47) "Official prescription form" means a
 1-41 prescription form that is used for a Schedule II controlled
 1-42 substance under Section 481.0755 and contains the prescription
 1-43 information required by Section 481.0755(e) [481.075].

1-44 SECTION 3. Section 481.003(a), Health and Safety Code, is
 1-45 amended to read as follows:

1-46 (a) The director may adopt rules to administer and enforce
 1-47 this chapter, other than Sections [481.073,] 481.074, 481.075,
 1-48 481.0755, 481.0756, 481.076, 481.0761, 481.0762, 481.0763,
 1-49 481.07635, 481.07636, 481.0764, 481.0765, and 481.0766. The board
 1-50 may adopt rules to administer Sections [481.073,] 481.074, 481.075,
 1-51 481.0755, 481.0756, 481.076, 481.0761, 481.0762, 481.0763,
 1-52 481.07635, 481.07636, 481.0764, 481.0765, and 481.0766.

1-53 SECTION 4. Section 481.074, Health and Safety Code, is
 1-54 amended by amending Subsections (b), (c), (e), (f), (g), (h), (k),
 1-55 and (q) and adding Subsections (b-1) and (b-2) to read as follows:

1-56 (b) Except in an emergency as defined by board rule under
 1-57 Subsection (b-1) [of the board] or as otherwise provided by
 1-58 [Subsection (e) or] Section 481.075(j) or (m) or 481.0755, a person
 1-59 may not dispense or administer a controlled substance [listed in
 1-60 Schedule II without a written prescription of a practitioner on an
 1-61 official prescription form or] without an electronic prescription

2-1 that meets the requirements of and is completed by the practitioner
2-2 in accordance with Section 481.075.

2-3 (b-1) In an emergency as defined by board rule, a person may
2-4 dispense or administer a controlled substance [~~listed in Schedule~~
2-5 ~~II~~] on the oral or telephonically communicated prescription of a
2-6 practitioner. The person who administers or dispenses the
2-7 substance shall:

2-8 (1) if the person is a prescribing practitioner or a
2-9 pharmacist, promptly comply with Subsection (c); or

2-10 (2) if the person is not a prescribing practitioner or
2-11 a pharmacist, promptly write the oral or telephonically
2-12 communicated prescription and include in the written record of the
2-13 prescription the name, address, and Federal Drug Enforcement
2-14 Administration number issued for prescribing a controlled
2-15 substance in this state of the prescribing practitioner, all
2-16 information required to be provided by a practitioner under Section
2-17 481.075(e)(1), and all information required to be provided by a
2-18 dispensing pharmacist under Section 481.075(e)(2).

2-19 (b-2) In an emergency described by Subsection (b-1), an
2-20 agent designated in writing by a practitioner defined by Section
2-21 481.002(39)(A) may communicate a prescription by telephone. A
2-22 practitioner who designates a different agent shall designate that
2-23 agent in writing and maintain the designation in the same manner in
2-24 which the practitioner initially designated an agent under this
2-25 subsection. On the request of a pharmacist, a practitioner shall
2-26 furnish a copy of the written designation. This subsection does not
2-27 relieve a practitioner or the practitioner's designated agent from
2-28 the requirement of Subchapter A, Chapter 562, Occupations Code. A
2-29 practitioner is personally responsible for the actions of the
2-30 designated agent in communicating a prescription to a pharmacist.

2-31 (c) Not later than the seventh day after the date a
2-32 prescribing practitioner authorizes an emergency oral or
2-33 telephonically communicated prescription, the prescribing
2-34 practitioner shall cause an an [~~a written or~~] electronic prescription,
2-35 completed in the manner required by Section 481.075, to be
2-36 delivered to the dispensing pharmacist at the pharmacy where the
2-37 prescription was dispensed. [~~A written prescription may be~~
2-38 ~~delivered in person or by mail. The envelope of a prescription~~
2-39 ~~delivered by mail must be postmarked not later than the seventh day~~
2-40 ~~after the date the prescription was authorized. On receipt of a~~
2-41 ~~written prescription, the dispensing pharmacy shall file the~~
2-42 ~~transcription of the telephonically communicated prescription and~~
2-43 ~~the pharmacy copy and shall send information to the board as~~
2-44 ~~required by Section 481.075.] On receipt of the an] electronic
2-45 prescription, the pharmacist shall annotate the electronic
2-46 prescription record with the original authorization and date of the
2-47 emergency oral or telephonically communicated prescription.~~

2-48 (e) The partial filling of a prescription for a controlled
2-49 substance listed in Schedule II is permissible in accordance with
2-50 applicable federal law[~~, if the pharmacist is unable to supply the~~
2-51 ~~full quantity called for in a written or electronic prescription or~~
2-52 ~~emergency oral prescription and the pharmacist makes a notation of~~
2-53 ~~the quantity supplied on the face of the written prescription, on~~
2-54 ~~the written record of the emergency oral prescription, or in the~~
2-55 ~~electronic prescription record. The remaining portion of the~~
2-56 ~~prescription may be filled within 72 hours of the first partial~~
2-57 ~~filling; however, if the remaining portion is not or cannot be~~
2-58 ~~filled within the 72-hour period, the pharmacist shall so notify~~
2-59 ~~the prescribing individual practitioner. No further quantity may~~
2-60 ~~be supplied beyond 72 hours without a new prescription].~~

2-61 (f) A prescription for a Schedule II controlled substance
2-62 for a patient in a long-term care facility (LTCF) or for a hospice
2-63 patient with a medical diagnosis documenting a terminal illness may
2-64 be filled in partial quantities to include individual dosage units.
2-65 If there is any question about whether a hospice patient may be
2-66 classified as having a terminal illness, the pharmacist must
2-67 contact the practitioner before partially filling the
2-68 prescription. Both the pharmacist and the practitioner have a
2-69 corresponding responsibility to assure that the controlled

3-1 substance is for a terminally ill hospice patient. The pharmacist
 3-2 must record the prescription [~~on an official prescription form or~~]
 3-3 in the electronic prescription record and must indicate [~~on the~~
 3-4 ~~official prescription form or~~] in the electronic prescription
 3-5 record whether the patient is a "terminally ill hospice patient" or
 3-6 an "LTCF patient." A prescription that is partially filled and does
 3-7 not contain the notation "terminally ill hospice patient" or "LTCF
 3-8 patient" is considered to have been filled in violation of this
 3-9 chapter. For each partial filling, the dispensing pharmacist shall
 3-10 record [~~on the back of the official prescription form or~~] in the
 3-11 electronic prescription record the date of the partial filling, the
 3-12 quantity dispensed, the remaining quantity authorized to be
 3-13 dispensed, and the identification of the dispensing pharmacist.
 3-14 Before any subsequent partial filling, the pharmacist must
 3-15 determine that the additional partial filling is necessary. The
 3-16 total quantity of Schedule II controlled substances dispensed in
 3-17 all partial fillings may not exceed the total quantity prescribed.
 3-18 Schedule II prescriptions for patients in a long-term care facility
 3-19 or hospice patients with a medical diagnosis documenting a terminal
 3-20 illness are valid for a period not to exceed 60 days following the
 3-21 issue date unless sooner terminated by discontinuance of the
 3-22 medication.

3-23 (g) A person may not dispense a controlled substance in
 3-24 Schedule III or IV that is a prescription drug under the Federal
 3-25 Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.) without
 3-26 a [~~written, electronic, oral, or telephonically communicated~~]
 3-27 prescription of a practitioner defined by Section 481.002(39)(A) or
 3-28 (D), except that the practitioner may dispense the substance
 3-29 directly to an ultimate user. A prescription for a controlled
 3-30 substance listed in Schedule III or IV may not be filled or refilled
 3-31 later than six months after the date on which the prescription is
 3-32 issued and may not be refilled more than five times, unless the
 3-33 prescription is renewed by the practitioner. A prescription under
 3-34 this subsection must comply with other applicable state and federal
 3-35 laws.

3-36 (h) A pharmacist may dispense a controlled substance listed
 3-37 in Schedule III, IV, or V under a [~~written, electronic, oral, or~~
 3-38 ~~telephonically communicated~~] prescription issued by a practitioner
 3-39 defined by Section 481.002(39)(C) [~~and~~] only if the pharmacist
 3-40 determines that the prescription was issued for a valid medical
 3-41 purpose and in the course of professional practice. A prescription
 3-42 described by [~~issued under~~] this subsection may not be filled or
 3-43 refilled later than six months after the date the prescription is
 3-44 issued and may not be refilled more than five times, unless the
 3-45 prescription is renewed by the practitioner.

3-46 (k) A prescription for a controlled substance must show:

- 3-47 (1) the quantity of the substance prescribed:
 3-48 (A) [~~numerically, followed by the number written~~
 3-49 ~~as a word, if the prescription is written,~~
 3-50 [~~(B)~~] numerically, if the prescription is
 3-51 electronic; or
 3-52 (B) [~~(C)~~] if the prescription is communicated
 3-53 orally or telephonically, as transcribed by the receiving
 3-54 pharmacist;
- 3-55 (2) the date of issue;
 3-56 (2-a) if the prescription is issued for a Schedule II
 3-57 controlled substance to be filled at a later date under Subsection
 3-58 (d-1), the earliest date on which a pharmacy may fill the
 3-59 prescription;
- 3-60 (3) the name, address, and date of birth or age of the
 3-61 patient or, if the controlled substance is prescribed for an
 3-62 animal, the species of the animal and the name and address of its
 3-63 owner;
- 3-64 (4) the name and strength of the controlled substance
 3-65 prescribed;
- 3-66 (5) the directions for use of the controlled
 3-67 substance;
- 3-68 (6) the intended use of the substance prescribed
 3-69 unless the practitioner determines the furnishing of this

4-1 information is not in the best interest of the patient; and
 4-2 (7) the name, address, Federal Drug Enforcement
 4-3 Administration number, and telephone number of the practitioner at
 4-4 the practitioner's usual place of business [~~which must be legibly~~
 4-5 ~~printed or stamped on a written prescription; and~~

4-6 [~~(8) if the prescription is handwritten, the signature~~
 4-7 ~~of the prescribing practitioner].~~

4-8 (q) Each dispensing pharmacist shall send all required
 4-9 information [~~including any information required to complete the~~
 4-10 ~~Schedule III through V prescription forms,~~] to the board by
 4-11 electronic transfer or another form approved by the board not later
 4-12 than the next business day after the date the prescription is
 4-13 completely filled.

4-14 SECTION 5. The heading to Section 481.075, Health and
 4-15 Safety Code, is amended to read as follows:

4-16 Sec. 481.075. SCHEDULE II PRESCRIPTIONS [OFFICIAL
 4-17 PRESCRIPTION PROGRAM].

4-18 SECTION 6. Sections 481.075(a), (e), (g), (h), (i), and
 4-19 (j), Health and Safety Code, are amended to read as follows:

4-20 (a) A practitioner who prescribes a controlled substance
 4-21 listed in Schedule II shall, except as provided by Section
 4-22 481.074(b-1) or 481.0755 or a rule adopted under Section 481.0761,
 4-23 record the prescription [~~on an official prescription form or~~] in an
 4-24 electronic prescription that includes the information required by
 4-25 this section.

4-26 (e) Each [~~official prescription form or electronic~~
 4-27 prescription used to prescribe a Schedule II controlled substance
 4-28 must contain:

4-29 (1) information provided by the prescribing
 4-30 practitioner, including:

4-31 (A) the date the prescription is issued;
 4-32 (B) the controlled substance prescribed;
 4-33 (C) the quantity of controlled substance
 4-34 prescribed, shown [+

4-35 [~~(i)] numerically [~~followed by the number~~
 4-36 ~~written as a word, if the prescription is written; or~~~~

4-37 [~~(ii)] numerically, if the prescription is~~
 4-38 ~~electronic];~~

4-39 (D) the intended use of the controlled substance,
 4-40 or the diagnosis for which the controlled substance [~~it~~] is
 4-41 prescribed, and the instructions for use of the substance;

4-42 (E) the practitioner's name, address, and
 4-43 Federal Drug Enforcement Administration number issued for
 4-44 prescribing a controlled substance in this state;

4-45 (F) the name, address, and date of birth or age of
 4-46 the person for whom the controlled substance is prescribed; and

4-47 (G) if the prescription is issued to be filled at
 4-48 a later date under Section 481.074(d-1), the earliest date on which
 4-49 a pharmacy may fill the prescription;

4-50 (2) information provided by the dispensing
 4-51 pharmacist, including the date the prescription is filled; and

4-52 (3) [~~for a written prescription, the signatures of the~~
 4-53 ~~prescribing practitioner and the dispensing pharmacist or for an~~
 4-54 ~~electronic prescription,~~] the prescribing practitioner's
 4-55 electronic signature or other secure method of validation
 4-56 authorized by federal law.

4-57 (g) Except for an emergency oral or telephonically
 4-58 communicated prescription described by [~~prescribed under~~] Section
 4-59 481.074(b-1) [~~481.074(b)~~], the prescribing practitioner shall:

4-60 (1) record [~~legibly fill in,~~] or direct a designated
 4-61 agent to record [~~legibly fill in, on the official prescription form~~
 4-62 ~~or~~] in the electronic prescription [~~7~~] each item of information
 4-63 required to be provided by the prescribing practitioner under
 4-64 Subsection (e)(1), unless the practitioner determines that:

4-65 (A) under rule adopted by the board for this
 4-66 purpose, it is unnecessary for the practitioner or the
 4-67 practitioner's agent to provide the patient identification number;
 4-68 or

4-69 (B) it is not in the best interest of the patient

5-1 for the practitioner or practitioner's agent to provide information
 5-2 regarding the intended use of the controlled substance or the
 5-3 diagnosis for which it is prescribed; and

5-4 (2) ~~[sign the official prescription form and give the~~
 5-5 ~~form to the person authorized to receive the prescription or, in the~~
 5-6 ~~case of an electronic prescription,]~~ electronically sign or
 5-7 validate the electronic prescription as authorized by federal law
 5-8 and transmit the prescription to the dispensing pharmacy.

5-9 (h) In the case of an emergency oral or telephonically
 5-10 communicated prescription described by ~~[prescribed under]~~ Section
 5-11 481.074(b-1) ~~[481.074(b)]~~, the prescribing practitioner shall give
 5-12 the dispensing pharmacy the information needed to complete the
 5-13 ~~[official prescription form or]~~ electronic prescription record.

5-14 (i) Each dispensing pharmacist shall:

5-15 (1) ~~[fill in on the official prescription form or]~~
 5-16 note in the electronic prescription record each item of information
 5-17 given orally to the dispensing pharmacy under Subsection (h) and
 5-18 the date the prescription is filled~~[,]~~ and~~+~~

5-19 ~~[(A) for a written prescription, fill in the~~
 5-20 ~~dispensing pharmacist's signature, or~~

5-21 ~~[(B) for an electronic prescription,]~~
 5-22 appropriately record the identity of the dispensing pharmacist in
 5-23 the electronic prescription record;

5-24 (2) retain with the records of the pharmacy for at
 5-25 least two years:

5-26 (A) ~~[the official prescription form or]~~ the
 5-27 electronic prescription record~~[, as applicable];~~ and

5-28 (B) the name or other patient identification
 5-29 required by Section 481.074(m) or (n); and

5-30 (3) send all required information, including any
 5-31 information required to complete an ~~[official prescription form or]~~
 5-32 electronic prescription record, to the board by electronic transfer
 5-33 or another form approved by the board not later than the next
 5-34 business day after the date the prescription is completely filled.

5-35 (j) A medication order written for a patient who is admitted
 5-36 to a hospital at the time the medication order is written and filled
 5-37 is not required to be recorded ~~[on an official prescription form or]~~
 5-38 in an electronic prescription record that meets the requirements of
 5-39 this section.

5-40 SECTION 7. Subchapter C, Chapter 481, Health and Safety
 5-41 Code, is amended by adding Sections 481.0755 and 481.0756 to read as
 5-42 follows:

5-43 Sec. 481.0755. WRITTEN, ORAL, AND TELEPHONICALLY
 5-44 COMMUNICATED PRESCRIPTIONS. (a) Notwithstanding Sections 481.074
 5-45 and 481.075, a prescription for a controlled substance is not
 5-46 required to be issued electronically and may be issued in writing if
 5-47 the prescription is issued:

5-48 (1) by a veterinarian;

5-49 (2) in circumstances in which electronic prescribing
 5-50 is not available due to temporary technological or electronic
 5-51 failure, as prescribed by board rule;

5-52 (3) by a practitioner to be dispensed by a pharmacy
 5-53 located outside this state, as prescribed by board rule;

5-54 (4) when the prescriber and dispenser are in the same
 5-55 location or under the same license;

5-56 (5) in circumstances in which necessary elements are
 5-57 not supported by the most recently implemented national data
 5-58 standard that facilitates electronic prescribing;

5-59 (6) for a drug for which the United States Food and
 5-60 Drug Administration requires additional information in the
 5-61 prescription that is not possible with electronic prescribing;

5-62 (7) for a non-patient-specific prescription pursuant
 5-63 to a standing order, approved protocol for drug therapy,
 5-64 collaborative drug management, or comprehensive medication
 5-65 management, in response to a public health emergency or in other
 5-66 circumstances in which the practitioner may issue a
 5-67 non-patient-specific prescription;

5-68 (8) for a drug under a research protocol;

5-69 (9) by a practitioner who has received a waiver under

6-1 Section 481.0756 from the requirement to use electronic
6-2 prescribing;

6-3 (10) under circumstances in which the practitioner has
6-4 the present ability to submit an electronic prescription but
6-5 reasonably determines that it would be impractical for the patient
6-6 to obtain the drugs prescribed under the electronic prescription in
6-7 a timely manner and that a delay would adversely impact the
6-8 patient's medical condition; or

6-9 (11) before January 1, 2021.

6-10 (b) A dispensing pharmacist who receives a controlled
6-11 substance prescription in a manner other than electronically is not
6-12 required to verify that the prescription is exempt from the
6-13 requirement that it be submitted electronically. The pharmacist
6-14 may dispense a controlled substance pursuant to an otherwise valid
6-15 written, oral, or telephonically communicated prescription
6-16 consistent with the requirements of this subchapter.

6-17 (c) Except in an emergency, a practitioner must use a
6-18 written prescription to submit a prescription described by
6-19 Subsection (a). In an emergency, the practitioner may submit an
6-20 oral or telephonically communicated prescription as authorized
6-21 under Section 481.074(b-1).

6-22 (d) A written prescription for a controlled substance other
6-23 than a Schedule II controlled substance must include the
6-24 information required under Section 481.074(k) and the signature of
6-25 the prescribing practitioner.

6-26 (e) A written prescription for a Schedule II controlled
6-27 substance must be on an official prescription form and include the
6-28 information required for an electronic prescription under Section
6-29 481.075(e), the signature of the practitioner, and the signature of
6-30 the dispensing pharmacist after the prescription is filled.

6-31 (f) The board by rule shall authorize a practitioner to
6-32 determine whether it is necessary to obtain a particular patient
6-33 identification number and to provide that number on the official
6-34 prescription form.

6-35 (g) On request of a practitioner, the board shall issue
6-36 official prescription forms to the practitioner for a fee covering
6-37 the actual cost of printing, processing, and mailing the forms.
6-38 Before mailing or otherwise delivering prescription forms to a
6-39 practitioner, the board shall print on each form the number of the
6-40 form and any other information the board determines is necessary.

6-41 (h) Each official prescription form must be sequentially
6-42 numbered.

6-43 (i) A person may not obtain an official prescription form
6-44 unless the person is a practitioner as defined by Section
6-45 481.002(39)(A) or an institutional practitioner.

6-46 (j) Not more than one Schedule II prescription may be
6-47 recorded on an official prescription form.

6-48 (k) Not later than the 30th day after the date a
6-49 practitioner's Federal Drug Enforcement Administration number or
6-50 license to practice has been denied, suspended, canceled,
6-51 surrendered, or revoked, the practitioner shall return to the board
6-52 all official prescription forms in the practitioner's possession
6-53 that have not been used for prescriptions.

6-54 (l) Each prescribing practitioner:

6-55 (1) may use an official prescription form only to
6-56 submit a prescription described by Subsection (a);

6-57 (2) shall date or sign an official prescription form
6-58 only on the date the prescription is issued; and

6-59 (3) shall take reasonable precautionary measures to
6-60 ensure that an official prescription form issued to the
6-61 practitioner is not used by another person to violate this
6-62 subchapter or a rule adopted under this subchapter.

6-63 (m) In the case of an emergency oral or telephonically
6-64 communicated prescription described by Section 481.074(b-1), the
6-65 prescribing practitioner shall give the dispensing pharmacy the
6-66 information needed to complete the official prescription form if
6-67 the pharmacy is not required to use the electronic prescription
6-68 record.

6-69 (n) Each dispensing pharmacist receiving an oral or

7-1 telephonically communicated prescription under Subsection (m)
7-2 shall:

7-3 (1) fill in on the official prescription form each
7-4 item of information given orally to the dispensing pharmacy under
7-5 Subsection (m) and the date the prescription is filled and fill in
7-6 the dispensing pharmacist's signature;

7-7 (2) retain with the records of the pharmacy for at
7-8 least two years:

7-9 (A) the official prescription form; and

7-10 (B) the name or other patient identification
7-11 required by Section 481.074(m) or (n); and

7-12 (3) send all required information, including any
7-13 information required to complete an official prescription form, to
7-14 the board by electronic transfer or another form approved by the
7-15 board not later than the next business day after the date the
7-16 prescription is completely filled.

7-17 Sec. 481.0756. WAIVERS FROM ELECTRONIC PRESCRIBING. (a)
7-18 The appropriate regulatory agency that issued the license,
7-19 certification, or registration to a prescriber is authorized to
7-20 grant a prescriber a waiver from the electronic prescribing
7-21 requirement under the provisions of this section.

7-22 (b) The board shall convene an interagency workgroup that
7-23 includes representatives of each regulatory agency that issues a
7-24 license, certification, or registration to a prescriber.

7-25 (c) The work group described by Subsection (b) shall
7-26 establish recommendations and standards for circumstances in which
7-27 a waiver from the electronic prescribing requirement is appropriate
7-28 and a process under which a prescriber may request and receive a
7-29 waiver.

7-30 (d) The board shall adopt rules establishing the
7-31 eligibility for a waiver, including:

7-32 (1) economic hardship;

7-33 (2) technological limitations not reasonably within
7-34 the control of the prescriber; or

7-35 (3) other exceptional circumstances demonstrated by
7-36 the prescriber.

7-37 (e) Each regulatory agency that issues a license,
7-38 certification, or registration to a prescriber shall adopt rules
7-39 for the granting of waivers consistent with the board rules adopted
7-40 under Subsection (d).

7-41 (f) A waiver may be issued to a prescriber for a period of
7-42 one year. A prescriber may reapply for a subsequent waiver not
7-43 earlier than the 30th day before the date the waiver expires if the
7-44 circumstances that necessitated the waiver continue.

7-45 SECTION 8. Sections 481.0761(c) and (d), Health and Safety
7-46 Code, are amended to read as follows:

7-47 (c) The board by rule may:

7-48 (1) ~~permit more than one prescription to be~~
7-49 ~~administered or dispensed and recorded on one prescription form for~~
7-50 ~~a Schedule III through V controlled substance;~~

7-51 ~~[(1-a)]~~ establish a procedure for the issuance of
7-52 multiple prescriptions of a Schedule II controlled substance under
7-53 Section 481.074(d-1);

7-54 (2) remove from or return to the official prescription
7-55 program any aspect of a practitioner's or pharmacist's hospital
7-56 practice, including administering or dispensing;

7-57 (3) waive or delay any requirement relating to the
7-58 time or manner of reporting;

7-59 (4) establish compatibility protocols for electronic
7-60 data transfer hardware, software, or format, including any
7-61 necessary modifications for participation in a database described
7-62 by Section 481.076(j);

7-63 (5) establish a procedure to control the release of
7-64 information under Sections 481.074, 481.075, and 481.076; and

7-65 (6) establish a minimum level of prescription activity
7-66 below which a reporting activity may be modified or deleted.

7-67 (d) The board by rule shall authorize a practitioner to
7-68 determine whether it is necessary to obtain a particular patient
7-69 identification number and to provide that number ~~[on the official~~

8-1 ~~prescription form or~~] in the electronic prescription record.

8-2 SECTION 9. Subchapter C, Chapter 481, Health and Safety
8-3 Code, is amended by adding Sections 481.07635 and 481.07636 to read
8-4 as follows:

8-5 Sec. 481.07635. CONTINUING EDUCATION. (a) A person
8-6 authorized to receive information under Section 481.076(a)(5)
8-7 shall, not later than the first anniversary after the person is
8-8 issued a license, certification, or registration to prescribe or
8-9 dispense controlled substances under this chapter, complete two
8-10 hours of professional education related to approved procedures of
8-11 prescribing and monitoring controlled substances.

8-12 (b) A person authorized to receive information may annually
8-13 take the professional education course under this section to fulfil
8-14 hours toward the ethics education requirement of the person's
8-15 license, certification, or registration.

8-16 (c) The regulatory agency that issued the license,
8-17 certification, or registration to a person authorized to receive
8-18 information under Section 481.076(a)(5) shall approve professional
8-19 education to satisfy the requirements of this section.

8-20 Sec. 481.07636. OPIOID PRESCRIPTION LIMITS. (a) In this
8-21 section, "acute pain" means the normal, predicted, physiological
8-22 response to a stimulus such as trauma, disease, and operative
8-23 procedures. Acute pain is time limited. The term does not include:

8-24 (1) chronic pain;

8-25 (2) pain being treated as part of cancer care;

8-26 (3) pain being treated as part of hospice or other
8-27 end-of-life care; or

8-28 (4) pain being treated as part of palliative care.

8-29 (b) For the treatment of acute pain, a practitioner may not:

8-30 (1) issue a prescription for an opioid in an amount
8-31 that exceeds a 10-day supply; or

8-32 (2) provide for a refill of an opioid.

8-33 (c) Subsection (b) does not apply to a prescription for an
8-34 opioid approved by the United States Food and Drug Administration
8-35 for the treatment of substance addiction that is issued by a
8-36 practitioner for the treatment of substance addiction.

8-37 (d) A dispenser is not subject to criminal, civil, or
8-38 administrative penalties for dispensing or refusing to dispense a
8-39 controlled substance under a prescription that exceeds the limits
8-40 provided by Subsection (b).

8-41 SECTION 10. Section 481.128(a), Health and Safety Code, is
8-42 amended to read as follows:

8-43 (a) A registrant or dispenser commits an offense if the
8-44 registrant or dispenser knowingly:

8-45 (1) distributes, delivers, administers, or dispenses
8-46 a controlled substance in violation of Subchapter C [Sections
8-47 481.070-481.075];

8-48 (2) manufactures a controlled substance not
8-49 authorized by the person's Federal Drug Enforcement Administration
8-50 registration or distributes or dispenses a controlled substance not
8-51 authorized by the person's registration to another registrant or
8-52 other person;

8-53 (3) refuses or fails to make, keep, or furnish a
8-54 record, report, notification, order form, statement, invoice, or
8-55 information required by this chapter;

8-56 (4) prints, manufactures, possesses, or produces an
8-57 official prescription form without the approval of the board;

8-58 (5) delivers or possesses a counterfeit official
8-59 prescription form;

8-60 (6) refuses an entry into a premise for an inspection
8-61 authorized by this chapter;

8-62 (7) refuses or fails to return an official
8-63 prescription form as required by Section 481.0755(k) [~~481.075(k)~~];

8-64 (8) refuses or fails to make, keep, or furnish a
8-65 record, report, notification, order form, statement, invoice, or
8-66 information required by a rule adopted by the director or the board;
8-67 or

8-68 (9) refuses or fails to maintain security required by
8-69 this chapter or a rule adopted under this chapter.

9-1 SECTION 11. Section 481.129(a), Health and Safety Code, is
 9-2 amended to read as follows:

9-3 (a) A person commits an offense if the person knowingly:

9-4 (1) distributes as a registrant or dispenser a
 9-5 controlled substance listed in Schedule I or II, unless the person
 9-6 distributes the controlled substance as authorized under the
 9-7 federal Controlled Substances Act (21 U.S.C. Section 801 et seq.);

9-8 (2) uses in the course of manufacturing, prescribing,
 9-9 or distributing a controlled substance a Federal Drug Enforcement
 9-10 Administration registration number that is fictitious, revoked,
 9-11 suspended, or issued to another person;

9-12 (3) issues a prescription bearing a forged or
 9-13 fictitious signature;

9-14 (4) uses a prescription issued to another person to
 9-15 prescribe a Schedule II controlled substance;

9-16 (5) possesses, obtains, or attempts to possess or
 9-17 obtain a controlled substance or an increased quantity of a
 9-18 controlled substance:

9-19 (A) by misrepresentation, fraud, forgery,
 9-20 deception, or subterfuge;

9-21 (B) through use of a fraudulent prescription
 9-22 form; [✗]

9-23 (C) through use of a fraudulent oral or
 9-24 telephonically communicated prescription; or

9-25 (D) through the use of a fraudulent electronic
 9-26 prescription; or

9-27 (6) furnishes false or fraudulent material
 9-28 information in or omits material information from an application,
 9-29 report, record, or other document required to be kept or filed under
 9-30 this chapter.

9-31 SECTION 12. Section 32.024, Human Resources Code, is
 9-32 amended by adding Subsection (z-2) to read as follows:

9-33 (z-2) The limits on prescription drugs and medications
 9-34 under the medical assistance program provided by Subsections (z)
 9-35 and (z-1) do not apply to a prescription for an opioid for the
 9-36 treatment of acute pain under Section 481.07636, Health and Safety
 9-37 Code.

9-38 SECTION 13. Subchapter B, Chapter 32, Human Resources Code,
 9-39 is amended by adding Section 32.03115 to read as follows:

9-40 Sec. 32.03115. REIMBURSEMENT FOR MEDICATION-ASSISTED
 9-41 TREATMENT FOR OPIOID OR SUBSTANCE USE DISORDER. (a) In this
 9-42 section, "medication-assisted opioid or substance use disorder
 9-43 treatment" means the use of methadone, buprenorphine, oral
 9-44 buprenorphine/naloxone, or naltrexone to treat opioid or substance
 9-45 use disorder.

9-46 (b) Notwithstanding Sections 531.072 and 531.073,
 9-47 Government Code, or any other law and subject to Subsections (c) and
 9-48 (d), the commission shall provide medical assistance reimbursement
 9-49 for medication-assisted opioid or substance use disorder treatment
 9-50 without requiring a recipient of medical assistance or health care
 9-51 provider to obtain prior authorization or precertification for the
 9-52 treatment, except as needed to minimize the opportunity for fraud,
 9-53 waste, or abuse.

9-54 (c) The duty to provide medical assistance reimbursement
 9-55 for medication-assisted opioid or substance use disorder treatment
 9-56 under Subsection (b) does not apply with respect to:

9-57 (1) a prescription for methadone;

9-58 (2) a recipient for whom medication-assisted opioid or
 9-59 substance use disorder treatment is determined to be medically
 9-60 contraindicated by the recipient's physician; or

9-61 (3) a recipient who is subject to an age-related
 9-62 restriction applicable to medication-assisted opioid or substance
 9-63 use disorder treatment.

9-64 (d) The commission may provide medical assistance
 9-65 reimbursement for medication-assisted opioid or substance use
 9-66 disorder treatment only if the treatment is prescribed to a
 9-67 recipient of medical assistance by a licensed health care provider
 9-68 who is authorized to prescribe methadone, buprenorphine, oral
 9-69 buprenorphine/naloxone, or naltrexone.

10-1 (e) This section expires August 31, 2023.

10-2 SECTION 14. Section 554.051(a-1), Occupations Code, is
10-3 amended to read as follows:

10-4 (a-1) The board may adopt rules to administer Sections
10-5 [~~481.073,~~ 481.074, 481.075, 481.0755, 481.0756, 481.076,
10-6 481.0761, 481.0762, 481.0763, 481.07635, 481.07636, 481.0764,
10-7 481.0765, and 481.0766, Health and Safety Code.

10-8 SECTION 15. Section 565.003, Occupations Code, is amended
10-9 to read as follows:

10-10 Sec. 565.003. ADDITIONAL GROUNDS FOR DISCIPLINE REGARDING
10-11 APPLICANT FOR OR HOLDER OF NONRESIDENT PHARMACY LICENSE. Unless
10-12 compliance would violate the pharmacy or drug statutes or rules in
10-13 the state in which the pharmacy is located, the board may discipline
10-14 an applicant for or the holder of a nonresident pharmacy license if
10-15 the board finds that the applicant or license holder has failed to
10-16 comply with:

10-17 (1) Section 481.074, [~~or~~] 481.075, 481.0755,
10-18 481.0756, 481.076, 481.0761, 481.0762, 481.0763, 481.07635,
10-19 481.07636, 481.0764, 481.0765, or 481.0766, Health and Safety Code;

10-20 (2) Texas substitution requirements regarding:

10-21 (A) the practitioner's directions concerning
10-22 generic substitution;

10-23 (B) the patient's right to refuse generic
10-24 substitution; or

10-25 (C) notification to the patient of the patient's
10-26 right to refuse substitution;

10-27 (3) any board rule relating to providing drug
10-28 information to the patient or the patient's agent in written form or
10-29 by telephone; or

10-30 (4) any board rule adopted under Section 554.051(a)
10-31 and determined by the board to be applicable under Section
10-32 554.051(b).

10-33 SECTION 16. Sections 481.073, 481.074(o) and (p), and
10-34 481.075(b), (c), (d), (f), (k), and (l), Health and Safety Code, are
10-35 repealed.

10-36 SECTION 17. A person who holds a license, certification, or
10-37 registration to prescribe or dispense a controlled substance issued
10-38 before September 1, 2020, is required to take the continuing
10-39 education course provided by Section 481.07635, Health and Safety
10-40 Code, as added by this Act, not later than September 1, 2021.

10-41 SECTION 18. If before implementing any provision of this
10-42 Act a state agency determines that a waiver or authorization from a
10-43 federal agency is necessary for implementation of that provision,
10-44 the agency affected by the provision shall request the waiver or
10-45 authorization and may delay implementing that provision until the
10-46 waiver or authorization is granted.

10-47 SECTION 19. This Act takes effect September 1, 2019.

10-48 * * * * *